$TCRT
Alaunos Therapeutics, Inc.

2015 Q1 Form 10-K Financial Statement

#000119312515065956 Filed on February 26, 2015

View on sec.gov

Income Statement

Concept 2015 Q1 2014 2013 Q4
Revenue $270.0K $1.370M $200.0K
YoY Change 35.0% 71.25% 0.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.250M $12.17M $4.200M
YoY Change 23.55% -22.29% 3.45%
% of Gross Profit
Research & Development $74.25M $32.71M $2.720M
YoY Change 1034.96% -23.68% -92.22%
% of Gross Profit
Depreciation & Amortization $120.0K $460.0K $160.0K
YoY Change 0.0% -37.84% -15.79%
% of Gross Profit
Operating Expenses $74.25M $32.71M $6.920M
YoY Change 1034.96% -23.68% -82.27%
Operating Profit -$78.23M -$43.50M -$6.719M
YoY Change 699.54% -24.63% -82.7%
Interest Expense $0.00 $11.72M -$1.790M
YoY Change -100.0% 884.87% -120.89%
% of Operating Profit
Other Income/Expense, Net -$4.000K -$5.000K -$390.0K
YoY Change -55.56% -99.14% -880.0%
Pretax Income -$78.23M -$31.78M -$8.900M
YoY Change 705.66% -44.35% -70.56%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$78.23M -$31.78M -$8.903M
YoY Change 705.59% -44.35% -70.54%
Net Earnings / Revenue -28974.44% -2319.78% -4451.5%
Basic Earnings Per Share
Diluted Earnings Per Share -$0.69 -$0.31 -$0.09
COMMON SHARES
Basic Shares Outstanding 114.7M shares 83.70M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q1 2014 2013 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $129.7M $42.80M $68.20M
YoY Change 114.74% -37.24% -6.96%
Cash & Equivalents $129.7M $42.80M $68.20M
Short-Term Investments
Other Short-Term Assets $900.0K $1.100M $1.900M
YoY Change -43.75% -42.11% -72.46%
Inventory
Prepaid Expenses
Receivables $100.0K $100.0K $100.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $130.6M $44.10M $70.30M
YoY Change 110.65% -37.27% -12.43%
LONG-TERM ASSETS
Property, Plant & Equipment $426.0K $500.0K $801.0K
YoY Change -37.26% -37.5% -59.83%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $491.0K $600.0K $528.0K
YoY Change -5.03% -14.29% -47.25%
Total Long-Term Assets $1.045M $1.100M $1.457M
YoY Change -21.07% -26.67% -53.42%
TOTAL ASSETS
Total Short-Term Assets $130.6M $44.10M $70.30M
Total Long-Term Assets $1.045M $1.100M $1.457M
Total Assets $131.6M $45.20M $71.75M
YoY Change 107.89% -37.05% -13.97%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $779.0K $2.000M $422.0K
YoY Change 34.78% 400.0% -72.03%
Accrued Expenses $8.220M $7.200M $6.357M
YoY Change 42.91% 12.5% -61.51%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $10.49M $10.80M $7.791M
YoY Change 42.67% 38.46% -58.7%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $600.0K $600.0K $20.00K
YoY Change 2900.0% -95.89%
Total Long-Term Liabilities $600.0K $600.0K $20.00K
YoY Change 2900.0% -95.89%
TOTAL LIABILITIES
Total Short-Term Liabilities $10.49M $10.80M $7.791M
Total Long-Term Liabilities $600.0K $600.0K $20.00K
Total Liabilities $11.05M $11.40M $22.37M
YoY Change -48.85% -49.11% -36.01%
SHAREHOLDERS EQUITY
Retained Earnings -$450.8M -$340.8M
YoY Change 20.14%
Common Stock $571.4M $386.6M
YoY Change 47.03% 18.86%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $120.6M $33.80M $49.38M
YoY Change
Total Liabilities & Shareholders Equity $131.6M $45.20M $71.75M
YoY Change 107.89% -37.05% -13.97%

Cashflow Statement

Concept 2015 Q1 2014 2013 Q4
OPERATING ACTIVITIES
Net Income -$78.23M -$31.78M -$8.903M
YoY Change 705.59% -44.35% -70.54%
Depreciation, Depletion And Amortization $120.0K $460.0K $160.0K
YoY Change 0.0% -37.84% -15.79%
Cash From Operating Activities -$9.720M -$36.65M -$9.050M
YoY Change 12.37% -38.41% -57.91%
INVESTING ACTIVITIES
Capital Expenditures $17.00K $193.0K $10.00K
YoY Change 750.0% 46.21% -87.5%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change
Cash From Investing Activities -$20.00K -$190.0K -$10.00K
YoY Change 45.04% -87.5%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net -$94.07M $544.0K $57.60M
YoY Change -71368.18% -101.02%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 96.62M 11.44M 53.63M
YoY Change 11402.38% -79.02% -12017.78%
NET CHANGE
Cash From Operating Activities -9.720M -36.65M -9.050M
Cash From Investing Activities -20.00K -190.0K -10.00K
Cash From Financing Activities 96.62M 11.44M 53.63M
Net Change In Cash 86.88M -25.40M 44.57M
YoY Change -1212.42% 397.84% -302.32%
FREE CASH FLOW
Cash From Operating Activities -$9.720M -$36.65M -$9.050M
Capital Expenditures $17.00K $193.0K $10.00K
Free Cash Flow -$9.737M -$36.84M -$9.060M
YoY Change 12.54% -38.23% -58.02%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
114694324 shares
CY2006Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2006Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2006Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000 shares
CY2006Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2006Q2 ziop Shares Authorized
SharesAuthorized
280000000 shares
CY2013Q4 ziop Common Stock Price Per Share1
CommonStockPricePerShare1
3.50
CY2014Q2 dei Entity Public Float
EntityPublicFloat
327143169
CY2009Q4 ziop Estimated Fair Value Of Warrant
EstimatedFairValueOfWarrant
22900000
CY2011Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2011Q1 ziop Common Stock Price Per Share1
CommonStockPricePerShare1
4.80
CY2011Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.08
CY2011Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5138486 shares
CY2011Q4 us-gaap Stockholders Equity
StockholdersEquity
71607000
CY2011Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
275000
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
104713000
CY2012Q1 ziop Common Stock Price Per Share1
CommonStockPricePerShare1
5.20
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.11
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7147303 shares
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
48445000
CY2012Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
275000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
73306000
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
100159618 shares
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
100159618 shares
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.81
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3471935 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.01
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6747303 shares
CY2013Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
148604000
CY2013Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
1933000
CY2013Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
212000
CY2013Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2153000
CY2013Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
227000
CY2013Q4 us-gaap Other Additional Capital
OtherAdditionalCapital
3603000
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7791000
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
100000
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
422000
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-340831000
CY2013Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
386511000
CY2013Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6357000
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
49383000
CY2013Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
20000
CY2013Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
230000
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
71754000
CY2013Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
582000
CY2013Q4 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
252000
CY2013Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
800000
CY2013Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
238000
CY2013Q4 us-gaap Liabilities
Liabilities
22371000
CY2013Q4 us-gaap Deferred Rent Credit
DeferredRentCredit
1100000
CY2013Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
851000
CY2013Q4 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
255000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
68204000
CY2013Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
128000
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
801000
CY2013Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
145000
CY2013Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
148604000
CY2013Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1948000
CY2013Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1254000
CY2013Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
1074000
CY2013Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
25058000
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
6485430 shares
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2013Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2954000
CY2013Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
2654000
CY2013Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
66209000
CY2013Q4 us-gaap Assets
Assets
71754000
CY2013Q4 us-gaap Capitalized Computer Software Gross
CapitalizedComputerSoftwareGross
884000
CY2013Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2013Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
1028000
CY2013Q4 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
841000
CY2013Q4 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
153000
CY2013Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
528000
CY2013Q4 us-gaap Assets Current
AssetsCurrent
70297000
CY2013Q4 ziop Deferred Tax Assets Capitalized Acquisition Costs
DeferredTaxAssetsCapitalizedAcquisitionCosts
12323000
CY2013Q4 ziop Warrants Liability
WarrantsLiability
11776000
CY2013Q4 ziop Deferred Tax Assets Start Up And Organizational Costs
DeferredTaxAssetsStartUpAndOrganizationalCosts
41529000
CY2013Q4 ziop Deferred Tax Assets Depreciation
DeferredTaxAssetsDepreciation
129000
CY2013Q4 ziop Accrued Consulting Fees Current
AccruedConsultingFeesCurrent
3751000
CY2013Q4 ziop Accrued Manufacturing Costs Current
AccruedManufacturingCostsCurrent
547000
CY2013Q4 ziop Computer And Office Equipment Gross
ComputerAndOfficeEquipmentGross
1076000
CY2013Q4 ziop Accrued Preclinical Services Current
AccruedPreclinicalServicesCurrent
513000
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
104452105 shares
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
104452105 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
4.10
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.07
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3781162 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.10
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
8235076 shares
CY2014Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
26364 shares
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
4585769 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6505664 shares
CY2014Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
158570000
CY2014Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
280000
CY2014Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2615000
CY2014Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
212000
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10826000
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
104000
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2004000
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
3157000
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
0
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
501000
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-372612000
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
424000
CY2014Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
406349000
CY2014Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7182000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
33841000
CY2014Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
226000
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
45237000
CY2014Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
422000
CY2014Q4 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
768000
CY2014Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1360000
CY2014Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
238000
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
997000
CY2014Q4 us-gaap Liabilities
Liabilities
11396000
CY2014Q4 us-gaap Deferred Rent Credit
DeferredRentCredit
850000
CY2014Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
570000
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
1235000
CY2014Q4 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
417000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
42803000
CY2014Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
128000
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
531000
CY2014Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
145000
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
9084000
CY2014Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
158570000
CY2014Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1139000
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
9056000
CY2014Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1547000
CY2014Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
534000
CY2014Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
26112000
CY2014Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3146000
CY2014Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
4130000
CY2014Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
79050000
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due Future Minimum Sublease Rentals
OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals
1224000
CY2014Q4 us-gaap Assets
Assets
45237000
CY2014Q4 us-gaap Capitalized Computer Software Gross
CapitalizedComputerSoftwareGross
874000
CY2014Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2014Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
1181000
CY2014Q4 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
927000
CY2014Q4 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
251000
CY2014Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
491000
CY2014Q4 ziop Operating Leases Future Minimum Payments Due Net
OperatingLeasesFutureMinimumPaymentsDueNet
1933000
CY2014Q4 ziop Deferred Tax Assets Capitalized Acquisition Costs
DeferredTaxAssetsCapitalizedAcquisitionCosts
11376000
CY2014Q4 us-gaap Assets Current
AssetsCurrent
44087000
CY2013 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-59509000
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2013 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
1185000
CY2009 ziop Warrants To Purchase Aggregate Shares Of Common Stock
WarrantsToPurchaseAggregateSharesOfCommonStock
8206520 shares
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.8340 pure
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
2649900 shares
CY2013 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.68
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.51
CY2013 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.00 pure
CY2014Q4 ziop Deferred Tax Assets Start Up And Organizational Costs
DeferredTaxAssetsStartUpAndOrganizationalCosts
38562000
CY2014Q4 ziop Net Operating Loss Carryforward Excess Tax Deduction Related To Stock Based Compensation
NetOperatingLossCarryforwardExcessTaxDeductionRelatedToStockBasedCompensation
4400000
CY2014Q4 ziop Deferred Tax Assets Depreciation
DeferredTaxAssetsDepreciation
208000
CY2014Q4 ziop Accrued Consulting Fees Current
AccruedConsultingFeesCurrent
2802000
CY2014Q4 ziop Accrued Manufacturing Costs Current
AccruedManufacturingCostsCurrent
308000
CY2014Q4 ziop Computer And Office Equipment Gross
ComputerAndOfficeEquipmentGross
1094000
CY2014Q4 ziop Accrued Preclinical Services Current
AccruedPreclinicalServicesCurrent
2027000
CY2013Q4 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
57600000
CY2013Q4 ziop Common Stock Shares Sold
CommonStockSharesSold
16445000 shares
CY2011Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
3636926 shares
CY2011Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
11600000
CY2011Q1 ziop Common Stock Shares Sold
CommonStockSharesSold
2426235 shares
CY2012Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
52600000
CY2012Q1 ziop Common Stock Shares Sold
CommonStockSharesSold
10114401 shares
CY2009 ziop Class Of Warrant Term
ClassOfWarrantTerm
P5Y
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
2479732 shares
CY2013 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.04 pure
CY2013 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
85943175 shares
CY2013 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.46 pure
CY2013 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.01 pure
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0100 pure
CY2013 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
4.58
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y11D
CY2013 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.28
CY2013 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.66
CY2013 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34 pure
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.9596 pure
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0210 pure
CY2013 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
17639935 shares
CY2013 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
0.09 pure
CY2013 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.02 pure
CY2013 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
570168 shares
CY2013 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
-37000
CY2013 us-gaap Contracts Revenue
ContractsRevenue
800000
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.8522 pure
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
1099300 shares
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P5Y9M18D
CY2014 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.26
CY2013 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-473000
CY2013 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
87000
CY2013 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0
CY2013 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-4964000
CY2013 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-585000
CY2013 us-gaap Operating Income Loss
OperatingIncomeLoss
-57713000
CY2013 us-gaap Income Taxes Paid
IncomeTaxesPaid
0
CY2013 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
0
CY2013 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
498000
CY2013 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-579000
CY2013 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
600000
CY2013 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
132000
CY2013 us-gaap Net Income Loss
NetIncomeLoss
-57107000
CY2013 us-gaap Interest Paid
InterestPaid
0
CY2013 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3507000
CY2013 us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
-4000
CY2013 us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
800000
CY2013 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-800000
CY2013 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
42852000
CY2013 us-gaap Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities
UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
0
CY2013 us-gaap Increase Decrease In Other Deferred Liability
IncreaseDecreaseInOtherDeferredLiability
625000
CY2013 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
20000
CY2013 us-gaap Restructuring Charges
RestructuringCharges
1700000
CY2013 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
498000
CY2013 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-5102000
CY2013 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1000000
CY2013 us-gaap Depreciation And Amortization
DepreciationAndAmortization
738000
CY2013 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
54538000
CY2013 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
1000
CY2013 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-10159000
CY2013 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-131000
CY2013 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
58513000
CY2013 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
956000
CY2013 us-gaap Allocated Share Based Compensation Expense Net Of Tax
AllocatedShareBasedCompensationExpenseNetOfTax
3507000
CY2013 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
139000
CY2013 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15661000
CY2013 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1087000
CY2013 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
200000
CY2013 us-gaap Share Based Compensation
ShareBasedCompensation
3507000
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1400000
CY2013 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
0
CY2013 ziop Revenue Recognition Period
RevenueRecognitionPeriod
P75M
CY2013 ziop Effective Income Tax Rate Reconciliation Federal Research And Development Tax Grant
EffectiveIncomeTaxRateReconciliationFederalResearchAndDevelopmentTaxGrant
0.00 pure
CY2013 ziop Stock Issued During Period Value Stock Warrants Exercised
StockIssuedDuringPeriodValueStockWarrantsExercised
200000
CY2013 ziop Effective Income Tax Rate Reconciliation Uncertain Tax Positions
EffectiveIncomeTaxRateReconciliationUncertainTaxPositions
0.00 pure
CY2013 ziop Stock Issued During Period Shares Stock Warrants Exercised
StockIssuedDuringPeriodSharesStockWarrantsExercised
112808 shares
CY2013 ziop Class Of Warrant Or Right Exercised In Period
ClassOfWarrantOrRightExercisedInPeriod
135346 shares
CY2013 ziop Proceeds From Issuance Of Common Stock And Warrants Net
ProceedsFromIssuanceOfCommonStockAndWarrantsNet
53880000
CY2014 dei Document Type
DocumentType
10-K
CY2014 dei Entity Registrant Name
EntityRegistrantName
ZIOPHARM ONCOLOGY INC
CY2014 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
Yes
CY2014 dei Trading Symbol
TradingSymbol
ZIOP
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.58
CY2014 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2014 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2014 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.00 pure
CY2014 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-36650000
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
727801 shares
CY2014 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.02 pure
CY2014 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Use of Estimates</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Although the Company regularly assesses these estimates, actual results could differ from those estimates. Changes in estimates are recorded in the period in which they become known.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> The Company&#x2019;s most significant estimates and judgments used in the preparation of our financial statements are:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="5%">&#xA0;</td> <td valign="top" width="2%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left">Clinical trial expenses;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="5%">&#xA0;</td> <td valign="top" width="2%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left">Fair value measurements for stock based compensation and warrants; and</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="5%">&#xA0;</td> <td valign="top" width="2%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left">Income taxes.</td> </tr> </table> </div>
CY2014 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
101130710 shares
CY2014 dei Document Period End Date
DocumentPeriodEndDate
2014-12-31
CY2014 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.31 pure
CY2014 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.04 pure
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0174 pure
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y2M9D
CY2014 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
4.54
CY2014 dei Amendment Flag
AmendmentFlag
false
CY2014 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2014 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y9M18D
CY2014 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
4.95
CY2014 dei Entity Central Index Key
EntityCentralIndexKey
0001107421
CY2014 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.31
CY2014 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34 pure
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.9455 pure
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0211 pure
CY2014 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2014 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6650172 shares
CY2014 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <b><i>Concentrations of Credit Risk</i></b></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. The Company maintains cash accounts in commercial banks, which may, at times, exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk on cash and cash equivalents.</p> </div>
CY2014 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
0.03 pure
CY2014 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.04 pure
CY2014 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
613138 shares
CY2014 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2014 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
11723000
CY2014 us-gaap Contracts Revenue
ContractsRevenue
1373000
CY2014 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
10000000
CY2014 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-37000
CY2014 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0
CY2014 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-809000
CY2014 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
54000
CY2014 us-gaap Operating Income Loss
OperatingIncomeLoss
-43499000
CY2014 us-gaap Income Taxes Paid
IncomeTaxesPaid
0
CY2014 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
0
CY2014 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
544000
CY2014 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-5000
CY2014 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
193000
CY2014 us-gaap Net Income Loss
NetIncomeLoss
-31781000
CY2014 us-gaap Interest Paid
InterestPaid
0
CY2014 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4743000
CY2014 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1373000
CY2014 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
32706000
CY2014 us-gaap Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities
UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
0
CY2014 us-gaap Increase Decrease In Other Deferred Liability
IncreaseDecreaseInOtherDeferredLiability
-213000
CY2014 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-20000
CY2014 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
544000
CY2014 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-25401000
CY2014 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1200000
CY2014 us-gaap Depreciation And Amortization
DepreciationAndAmortization
462000
CY2014 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
11442000
CY2014 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
827000
CY2014 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-193000
CY2014 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
44872000
CY2014 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1386000
CY2014 us-gaap Allocated Share Based Compensation Expense Net Of Tax
AllocatedShareBasedCompensationExpenseNetOfTax
4743000
CY2014 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
79000
CY2014 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12166000
CY2014 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1582000
CY2014 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
10600000
CY2014 us-gaap Share Based Compensation
ShareBasedCompensation
4743000
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
2600000
CY2014 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
0
CY2014 ziop Effective Income Tax Rate Reconciliation Federal Research And Development Tax Grant
EffectiveIncomeTaxRateReconciliationFederalResearchAndDevelopmentTaxGrant
0.00 pure
CY2014 ziop Stock Issued During Period Value Stock Warrants Exercised
StockIssuedDuringPeriodValueStockWarrantsExercised
10654000
CY2014 ziop Effective Income Tax Rate Reconciliation Uncertain Tax Positions
EffectiveIncomeTaxRateReconciliationUncertainTaxPositions
0.00 pure
CY2014 ziop Warrants To Purchase Aggregate Shares Of Common Stock
WarrantsToPurchaseAggregateSharesOfCommonStock
184367 shares
CY2014 ziop Stock Issued During Period Shares Stock Warrants Exercised
StockIssuedDuringPeriodSharesStockWarrantsExercised
3725277 shares
CY2014 ziop Class Of Warrant Or Right Exercised In Period
ClassOfWarrantOrRightExercisedInPeriod
4004907 shares
CY2012 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-78832000
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2012 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2014 ziop Expected Net Proceeds From Issuance Of Common Stock
ExpectedNetProceedsFromIssuanceOfCommonStock
94600000
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.8336 pure
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
2309650 shares
CY2012 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.61
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.06
CY2012 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.00 pure
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
292533 shares
CY2012 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.05 pure
CY2012 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
78546112 shares
CY2012 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.49 pure
CY2012 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.02 pure
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0079 pure
CY2012 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
5.70
CY2012 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
4.36
CY2012 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.22
CY2012 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34 pure
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.8353 pure
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0113 pure
CY2012 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
19078496 shares
CY2012 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
0.10 pure
CY2012 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.01 pure
CY2012 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
8300 shares
CY2012 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
6050000
CY2012 us-gaap Contracts Revenue
ContractsRevenue
800000
CY2012 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
230000
CY2012 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-21000
CY2012 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0
CY2012 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
5599000
CY2012 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-48000
CY2012 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
412000
CY2012 us-gaap Operating Income Loss
OperatingIncomeLoss
-102169000
CY2012 us-gaap Income Taxes Paid
IncomeTaxesPaid
0
CY2012 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
0
CY2012 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
546000
CY2012 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-13000
CY2012 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1559000
CY2012 us-gaap Net Income Loss
NetIncomeLoss
-96132000
CY2012 us-gaap Interest Paid
InterestPaid
0
CY2012 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4880000
CY2012 us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
43000
CY2012 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-800000
CY2012 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
83446000
CY2012 us-gaap Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities
UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
0
CY2012 us-gaap Increase Decrease In Other Deferred Liability
IncreaseDecreaseInOtherDeferredLiability
244000
CY2012 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
546000
CY2012 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-31407000
CY2012 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1100000
CY2012 us-gaap Depreciation And Amortization
DepreciationAndAmortization
658000
CY2012 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
48984000
CY2012 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
5695000
CY2012 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
18694000
CY2012 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-1559000
CY2012 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
102969000
CY2012 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
30000
CY2012 us-gaap Allocated Share Based Compensation Expense Net Of Tax
AllocatedShareBasedCompensationExpenseNetOfTax
4880000
CY2012 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
266000
CY2012 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
19523000
CY2012 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-218000
CY2012 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
330000
CY2012 us-gaap Share Based Compensation
ShareBasedCompensation
4880000
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
11000
CY2012 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
0
CY2012 ziop Effective Income Tax Rate Reconciliation Federal Research And Development Tax Grant
EffectiveIncomeTaxRateReconciliationFederalResearchAndDevelopmentTaxGrant
0.00 pure
CY2012 ziop Stock Issued During Period Value Stock Warrants Exercised
StockIssuedDuringPeriodValueStockWarrantsExercised
742000
CY2012 ziop Effective Income Tax Rate Reconciliation Uncertain Tax Positions
EffectiveIncomeTaxRateReconciliationUncertainTaxPositions
0.00 pure
CY2012 ziop Stock Issued During Period Shares Stock Warrants Exercised
StockIssuedDuringPeriodSharesStockWarrantsExercised
259660 shares
CY2012 ziop Class Of Warrant Or Right Exercised In Period
ClassOfWarrantOrRightExercisedInPeriod
553914 shares
CY2012 ziop Proceeds From Issuance Of Common Stock And Warrants Net
ProceedsFromIssuanceOfCommonStockAndWarrantsNet
49170000
CY2013Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.15
CY2013Q1 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
10788000
CY2013Q1 us-gaap Contracts Revenue
ContractsRevenue
200000
CY2013Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-23583000
CY2013Q1 us-gaap Net Income Loss
NetIncomeLoss
-12799000
CY2013Q1 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
23783000
CY2014Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.10
CY2014Q1 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
82000
CY2014Q1 us-gaap Contracts Revenue
ContractsRevenue
200000
CY2014Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-9784000
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-9711000
CY2014Q1 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
9984000
CY2013Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.22
CY2013Q2 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-403000
CY2013Q2 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
18496000
CY2014Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.06
CY2014Q2 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
5600000
CY2014Q2 us-gaap Contracts Revenue
ContractsRevenue
200000
CY2014Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-11177000
CY2014Q2 us-gaap Net Income Loss
NetIncomeLoss
-5576000
CY2014Q2 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
11377000
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
-16713000
CY2013Q3 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
9315000
CY2013Q2 us-gaap Contracts Revenue
ContractsRevenue
200000
CY2013Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-18296000
CY2013Q2 us-gaap Net Income Loss
NetIncomeLoss
-18692000
CY2013Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.20
CY2013Q3 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-7407000
CY2013Q3 us-gaap Contracts Revenue
ContractsRevenue
200000
CY2013Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-9115000
CY2014Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.06
CY2014Q3 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
5847000
CY2014Q3 us-gaap Contracts Revenue
ContractsRevenue
633000
CY2014Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-11942000
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
-6093000
CY2014Q3 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
12575000
CY2013Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.09
CY2013Q4 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-1793000
CY2013Q4 us-gaap Contracts Revenue
ContractsRevenue
200000
CY2013Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-6719000
CY2013Q4 us-gaap Net Income Loss
NetIncomeLoss
-8903000
CY2013Q4 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
6919000
CY2014Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.09
CY2014Q4 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
194000
CY2014Q4 us-gaap Contracts Revenue
ContractsRevenue
340000
CY2014Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-10596000
CY2014Q4 us-gaap Net Income Loss
NetIncomeLoss
-10401000
CY2014Q4 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
10936000

Files In Submission

Name View Source Status
0001193125-15-065956-index-headers.html Edgar Link pending
0001193125-15-065956-index.html Edgar Link pending
0001193125-15-065956.txt Edgar Link pending
0001193125-15-065956-xbrl.zip Edgar Link pending
d867138d10k.htm Edgar Link pending
d867138dex231.htm Edgar Link pending
d867138dex311.htm Edgar Link pending
d867138dex312.htm Edgar Link pending
d867138dex321.htm Edgar Link pending
d867138dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
g867138g41y43.jpg Edgar Link pending
g867138g77h34.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
ziop-20141231.xml Edgar Link completed
ziop-20141231.xsd Edgar Link pending
ziop-20141231_cal.xml Edgar Link unprocessable
ziop-20141231_def.xml Edgar Link unprocessable
ziop-20141231_lab.xml Edgar Link unprocessable
ziop-20141231_pre.xml Edgar Link unprocessable